Company intelligence / Profile preview

Hedros Bio

Ownership: Private
Development stage: Preclinical

Overview

Trials with a leading shrimp genetics partner demonstrated that Hedros Bio's phage product reduces EMS-related mortality by up to 90 percent. In vivo trials challenged SPF shrimp lines with EMS doses 10 times higher than typical outbreak levels, with the phage cocktail protecting all shrimp lines and eliminating the target pathogen.

Therapeutic areas: Infectious Diseases
Modalities: Bacteriophages
Industry: Veterinary

Partnerships

Hatch BlueLeading shrimp genetics partner

Beyond the preview

Go deeper on Hedros Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hedros Bio.

Explore the full profile